MacuLogix Enters Canadian Distribution Agreement with Clarion Medical Technologies

Source: MacuLogix

MacuLogix has entered into an international distribution agreement with Clarion Medical Technologies, a Canadian provider of medical and aesthetic equipment and consumables. Effective immediately, Clarion will add the AdaptDx automated dark adaptometer to its Vision division’s portfolio of products.

“We are very pleased to partner with Clarion to expand our reach into Canada,” Armond Dantino, Vice President of Sales for MacuLogix, said in a company news release. “Bringing the AdaptDx to Canada is critical to preserving vision, as AMD accounts for 90% of new cases of legal blindness in Canada according to the Canadian Ophthalmological Society.”

“The AdaptDx is an exciting addition to Clarion’s expansive portfolio of revolutionary ophthalmic devices, lenses and nutraceuticals,” Dan Webb, Chairman of Clarion, Medical Technologies, said in the news release. “We take great pride in offering cutting-edge technology solutions to our Vision customers and are confident that Canadian eye care professionals will find greatvvalue in the AdaptDx for detecting and monitoring age-related macular degeneration.”

AMD has been identified as the leading cause of adult blindness in developed countries because diagnosing AMD at the earliest stages has been a challenge. The AdaptDx is the first commercially available dark adaptometer that can be used in clinical practice to detect AMD at a subclinical stage, before structural changes in the retina like drusen become visible. Patients are often asymptomatic, have good corrected visual acuity, and their retina appears normal upon clinical evaluation. Thankfully, research has shown that functional assessment of dark adaptation using the AdaptDx can radically improve diagnostic sensitivity and specificity by detecting the disease with 90% accuracy at least three years before structural changes such as drusen are visible, enabling clinicians to intervene before irreversible vision loss occurs.

Related Content